Single-Use Spherical Pulsed Ablation Catheter for Paroxysmal Atrial Fibrillation
torstai 3. syyskuuta 2026 päivittänyt: Shanghai Shineyo Medical Co., Ltd.
A Prospective, Multicenter, Randomized Controlled, Non-inferiority Clinical Trial Evaluating the Safety and Efficacy of Cardiac Pulsed Field Ablation Devices Combined With Single-use Spherical Pulsed Ablation Catheters in Treating Paroxysmal Atrial Fibrillation
The goal of this clinical trial is to learn if the cardiac pulsed field ablation system, composed of the cardiac pulsed field ablation device, the single-use spherical pulsed ablation catheter, and the optional cardiac three-dimensional mapping system, works to treat symptomatic, recurrent, drug-refractory paroxysmal atrial fibrillation. It will also learn about the safety of this set of investigational medical devices. The main questions it aims to answer are:
Does the combination of the cardiac pulsed field ablation device and the single-use spherical pulsed ablation catheter improve the 12-month post-procedure treatment success rate for participants with paroxysmal atrial fibrillation? What adverse events and medical problems do participants experience after receiving the investigational pulsed field ablation treatment? Researchers will compare the investigational pulsed field ablation therapy to the clinically recognized radiofrequency ablation therapy using the marketed Diagnostic/Ablation Deflectable Tip Catheter to verify the non-inferior effectiveness and safety of the test devices for treating paroxysmal atrial fibrillation.
Participants will:
Undergo screening assessments within 14 days before the procedure, including signing informed consent, completing medical history collection, physical vital sign checks, laboratory tests, 12-lead ECG, echocardiogram, baseline quality of life score evaluation, and confirmation of meeting all inclusion criteria without any exclusion criteria Be randomly assigned to either the investigational pulsed field ablation group or the control radiofrequency ablation group on the day of surgery Receive the assigned ablation procedure, with intra-operative recordings of core surgical parameters, pain score assessment, and investigational device performance evaluation Complete post-procedure assessments before discharge (within 7 days after surgery), including post-operative laboratory tests, pain follow-up, and recording of re-ablation, electrical cardioversion, readmission events, adverse events and concomitant medications Return for follow-up visits or complete telephone follow-ups at 1 month (±7 days), 3 months (±15 days), 6 months (±30 days) and 12 months (±30 days) after the procedure, which include physical vital sign checks, remote ECG monitoring (daily for the first 3 months after surgery, weekly from month 4 to month 12, and as needed when symptoms occur), 72-hour Holter and 12-lead ECG tests at the 6-month and 12-month visits, echocardiogram reexamination, repeated quality of life scoring, and continuous recording of arrhythmia recurrence, subsequent treatment events, adverse events and medication status Keep a symptom and ECG monitoring diary for the entire 12-month follow-up period after the procedure, as required by the trial protocol
Tutkimuksen yleiskatsaus
Tila
Ei vielä rekrytointia
Ehdot
Opintotyyppi
Interventio
Ilmoittautuminen (Arvioitu)
284
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskeluyhteys
- Nimi: Shuang Pan
- Puhelinnumero: 86-18621903981
- Sähköposti: panshuang@shineyomedical.com
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Ei
Kuvaus
Inclusion Criteria:
- Age ≥18 years and ≤75 years, without gender restriction
- Patients with symptomatic, recurrent, drug-refractory paroxysmal atrial fibrillation
- Subjects scheduled for atrial fibrillation catheter ablation
- Subjects who agree to participate in this study and voluntarily sign the informed consent form
Exclusion Criteria:
- Persistent atrial fibrillation, or atrial fibrillation secondary to electrolyte disturbance, thyroid disease, alcohol or other reversible/non-cardiac causes
- Anterior-posterior left atrial diameter (measured by MRI, CT or TTE) ≥55 mm
- Prior history of any atrial surgery or atrial endocardial/epicardial ablation, except cavotricuspid isthmus ablation or right-sided supraventricular tachycardia ablation
- Existing left atrial thrombus, atrial myxoma, atrial septal patch or shunt device
- Prior or planned concomitant left atrial appendage closure procedure at index procedure
- Diagnosis of hypertrophic cardiomyopathy
- History of congenital heart disease with residual anatomical or conduction abnormalities
- Hemodynamically significant valvular heart disease judged by investigator to be ineligible for enrollment
- Prior valve repair or valve replacement surgery
- Implanted pacemaker, implantable cardioverter-defibrillator or cardiac resynchronization therapy device
- NYHA functional class Ⅲ-Ⅳ
- Left ventricular ejection fraction (LVEF) ≤40%
- Symptomatic hypotension or uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >95 mmHg in two baseline measurements)
- Symptomatic resting bradycardia or type-second-degree or third-degree atrioventricular block
- Contraindication to systemic anticoagulation, or unwillingness to receive systemic anticoagulation
- Medical conditions that may interfere with study participation, assessment or treatment, significantly increase study-related risk, or alter study outcomes, including but not limited to: moderate-to-severe COPD, moderate-to-severe pulmonary hypertension, or diseases causing severe dyspnea or resting hypoxemia; renal insufficiency (eGFR<30 ml/min/1.73 m²) or history of hemodialysis or renal transplantation; active malignancy or treated malignancy within 24 months prior to enrollment (excluding basal cell or squamous cell skin carcinoma); active systemic infection
- Myocardial infarction, unstable angina, heart failure hospitalization within 3 months prior to enrollment; any cardiac interventional or open-heart surgery within 1 month prior to enrollment (coronary angiography excluded)
- Stroke (excluding silent stroke), transient ischemic attack or any thromboembolic event within 3 months prior to enrollment
- Expected survival less than 1 year
- Female subjects who are pregnant, lactating, or planning pregnancy during study period
- Participation in another interventional device clinical trial within 1 month before enrollment, or within 5 half-lives of last study drug for drug clinical trials
- Any other condition judged by investigator to make the subject unsuitable for this clinical trial
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Nelinkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Investigational Cardiac Pulsed Field Ablation (PFA) Arm
Intervention group receiving cardiac pulsed field ablation for paroxysmal atrial fibrillation
|
It consists of a cardiac pulsed electric field ablation apparatus and a single-use spherical pulsed ablation catheter, which can be paired with an optional cardiac three-dimensional mapping system to complete pulsed electric field ablation in the pulmonary vein antrum region, achieve pulmonary vein electrical isolation, and is indicated for the treatment of symptomatic, recurrent, drug-refractory paroxysmal atrial fibrillation.
|
|
Active Comparator: Control Radiofrequency (RF) Catheter Ablation Arm
Control group receiving conventional radiofrequency catheter ablation for paroxysmal atrial fibrillation
|
Using the commercially available diagnostic/ablation steerable-tip catheter in combination with a conventional clinical radiofrequency ablation device, point-by-point radiofrequency ablation is performed on the pulmonary vein antrum to achieve pulmonary vein electrical isolation.
This is the current standard clinical treatment for paroxysmal atrial fibrillation.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Proportion of participants with freedom from atrial fibrillation at 12 months post-index ablation (90-day post-procedure blanking period)
Aikaikkuna: 12 months post-index ablation
|
Treatment success at 12 months post-index ablation is defined as no amiodarone use and no repeat ablation during the 3-month post-procedure blanking period, except repeat ablation for CTI-dependent atrial flutter.
Following the end of the blanking period (i.e., 3 months to 12 months after the procedure), subjects shall have no use of Class I/III antiarrhythmic drugs, no repeat ablation, no electrical cardioversion (interventions for CTI-dependent atrial flutter excluded), and no episodes of atrial fibrillation, atrial flutter, or atrial tachycardia lasting ≥30 seconds confirmed by electrocardiogram or Holter monitoring (CTI-dependent atrial flutter excluded).
|
12 months post-index ablation
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Proportion of participants with treatment success at 12 months post-index ablation
Aikaikkuna: From the end of 30-day post-procedure blanking period to 12 months after the index ablation
|
From the end of 30-day post-procedure blanking period to 12 months after the index ablation
|
|
|
Acute procedural success rate on the day of index ablation
Aikaikkuna: On the day of index ablation (intra-procedure completion)
|
On the day of index ablation (intra-procedure completion)
|
|
|
Atrial fibrillation burden assessed by 72-hour Holter monitoring
Aikaikkuna: 6-month and 12-month follow-up; daily monitoring 1-3 months post-procedure, weekly monitoring 4-12 months post-procedure, additionally upon symptom occurrence
|
6-month and 12-month follow-up; daily monitoring 1-3 months post-procedure, weekly monitoring 4-12 months post-procedure, additionally upon symptom occurrence
|
|
|
Pain score at 2-hours and 24-hours after index ablation
Aikaikkuna: 2 hours after recovery from anesthesia; 24 hours post-index ablation
|
2 hours after recovery from anesthesia; 24 hours post-index ablation
|
|
|
Recurrence rate of early atrial tachyarrhythmias (atrial fibrillation / atrial flutter / atrial tachycardia)
Aikaikkuna: 1-month and 3-month post-index ablation
|
1-month and 3-month post-index ablation
|
|
|
Proportion of participants receiving electrical cardioversion, repeat ablation, emergency department visit or hospitalization due to documented recurrent atrial arrhythmia
Aikaikkuna: Prior to hospital discharge, 1-month, 3-month, 6-month, 12-month post-index ablation
|
Prior to hospital discharge, 1-month, 3-month, 6-month, 12-month post-index ablation
|
|
|
Proportion of participants with re-initiation of antiarrhythmic drugs
Aikaikkuna: 1-month, 3-month, 6-month, 12-month post-index ablation
|
1-month, 3-month, 6-month, 12-month post-index ablation
|
|
|
Time from index ablation to first documented recurrence of atrial fibrillation, atrial flutter or atrial tachycardia
Aikaikkuna: Up to 12-month post-index ablation, assessed at 1-,3-,6-,12-month visits
|
Up to 12-month post-index ablation, assessed at 1-,3-,6-,12-month visits
|
|
|
Symptom-free survival of participants
Aikaikkuna: 1-month, 3-month, 6-month, 12-month post-index ablation
|
1-month, 3-month, 6-month, 12-month post-index ablation
|
|
|
Change in Atrial Fibrillation Effect on Quality-of-Life (AFEQT) total score from baseline
Aikaikkuna: Baseline, 1-month, 3-month, 6-month, 12-month post-index ablation
|
The change from baseline in the total score of the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire.
Measurement tool: AFEQT questionnaire.
Unit: score.
|
Baseline, 1-month, 3-month, 6-month, 12-month post-index ablation
|
|
Performance evaluation of investigational device
Aikaikkuna: On the day of index ablation
|
On the day of index ablation
|
|
|
Incidence of major adverse events
Aikaikkuna: Within 7 days post-index ablation and up to 12 months post-index ablation
|
Within 7 days post-index ablation and up to 12 months post-index ablation
|
|
|
Incidence of device- or procedure-related stroke or transient ischemic attack (TIA)
Aikaikkuna: Through study completion, average of 12-month follow-up
|
Number of subjects experiencing device- or procedure-related stroke or transient ischemic attack (TIA).
Unit: percentage of subjects.
|
Through study completion, average of 12-month follow-up
|
|
Incidence of device- related serious adverse events (SAE)
Aikaikkuna: Through study completion, average of 12-month follow-up
|
Number of device-related serious adverse events divided by the total number of serious adverse events that occurred during follow-up.
Measurement tool: clinical adverse-event reporting.
Unit: percentage of SAE events.
|
Through study completion, average of 12-month follow-up
|
|
Laboratory values of myocardial injury biomarkers
Aikaikkuna: Within 48-hours post-index ablation
|
Laboratory values of myocardial injury biomarkers collected within 48-hours post-index ablation or prior to hospital discharge, whichever comes first.
Unit: laboratory value.
|
Within 48-hours post-index ablation
|
|
Incidence of hemolysis-associated renal injury
Aikaikkuna: Within 48-hours post-index ablation
|
Number of subjects with hemolysis-associated renal injury occurring within 48-hours post-index ablation or prior to hospital discharge, whichever comes first.
Unit: percentage of subjects.
|
Within 48-hours post-index ablation
|
|
Incidence of other adverse events (AE)
Aikaikkuna: Through study completion, average of 12-month follow-up
|
Number of subjects experiencing other adverse events (AEs) throughout the study period.
Unit: percentage of subjects.
|
Through study completion, average of 12-month follow-up
|
|
Total index ablation procedure duration
Aikaikkuna: Periprocedural
|
Total time duration of the index ablation procedure.
Unit: minutes.
|
Periprocedural
|
|
Left-atrial device dwell time during index ablation
Aikaikkuna: Periprocedural
|
Total dwell time of investigational device within left atrium during index ablation.
Unit: minutes.
|
Periprocedural
|
|
Pulmonary vein isolation (PVI) procedural time
Aikaikkuna: Intra-procedural
|
Time spent for pulmonary vein isolation (PVI) manipulation during index ablation.
Unit: minutes.
|
Intra-procedural
|
|
Total fluoroscopy time during index ablation
Aikaikkuna: Intra-procedural
|
Total fluoroscopy exposure time during index ablation.
Unit: minutes.
|
Intra-procedural
|
|
Total contrast media volume administered
Aikaikkuna: Intra-procedural
|
Total volume of contrast media used during index ablation.
Unit: mL.
|
Intra-procedural
|
|
Number of ablation energy deliveries
Aikaikkuna: Intra-procedural
|
Total count of ablation energy deliveries applied during index ablation.
Unit: number of subjects (count).
|
Intra-procedural
|
|
Incidence of other serious adverse events (SAE) throughout the study period
Aikaikkuna: Through study completion, average of 12-month follow-up
|
Number of subjects with other serious adverse events occurring during the entire study period.
Measurement tool: serious adverse-event reporting.
Unit: percentage of subjects.
|
Through study completion, average of 12-month follow-up
|
|
Laboratory values of inflammatory biomarkers
Aikaikkuna: Within 48-hours post-index ablation
|
Laboratory values of inflammatory biomarkers collected within 48-hours post-index ablation or prior to hospital discharge, whichever comes first.
Unit: laboratory value.
|
Within 48-hours post-index ablation
|
|
Change in EuroQol 5-Dimension 5-Level (EQ-5D-5L) utility score from baseline
Aikaikkuna: Baseline, 1-month, 3-month, 6-month, 12-month post-index ablation
|
The change from baseline in the utility index score calculated from the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire.
Measurement tool: EQ-5D-5L questionnaire.
Unit: index score.
|
Baseline, 1-month, 3-month, 6-month, 12-month post-index ablation
|
|
Proportion of procedure-related serious adverse events (SAEs) among all SAEs
Aikaikkuna: Through study completion, average of 12-month follow-up
|
Number of procedure-related serious adverse events divided by the total number of serious adverse events that occurred during follow-up.
Measurement tool: clinical adverse-event reporting.
Unit: percentage of SAE events.
|
Through study completion, average of 12-month follow-up
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Tiistai 1. syyskuuta 2026
Ensisijainen valmistuminen (Arvioitu)
Keskiviikko 1. maaliskuuta 2028
Opintojen valmistuminen (Arvioitu)
Torstai 1. kesäkuuta 2028
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Torstai 20. elokuuta 2026
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Torstai 3. syyskuuta 2026
Ensimmäinen Lähetetty (Todellinen)
Torstai 10. syyskuuta 2026
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Torstai 10. syyskuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Torstai 3. syyskuuta 2026
Viimeksi vahvistettu
Lauantai 1. elokuuta 2026
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- (2026)-(289)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
EI
IPD-suunnitelman kuvaus
Individual-participant-level data will not be shared with other researchers.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Yhdysvalloissa valmistettu ja sieltä viety tuote
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .